Zhongchao Inc. Established SID Liver Cancer Comprehensive-Disciplinary Physician Education Platform

Rhea-AI Summary

Zhongchao Inc. (NASDAQ: ZCMD) has launched its "Surgical-Interventional-Drug" (SID) platform aimed at enhancing liver cancer physician education in response to rising cases in China, where around 400,000 new liver cancer cases were reported in 2020. Designed to support comprehensive management and treatment strategies, the SID Platform has been accessed approximately 290,000 times by physicians. This initiative aligns with the National Health Commission's treatment guidelines and aims to improve ongoing professional development for healthcare providers, ultimately benefiting liver cancer patients.

Positive

• Launch of the SID platform for liver cancer physician education.
• The platform has been accessed about 290,000 times, indicating strong engagement.
• Supports comprehensive management of liver cancer, aligning with national treatment guidelines.

Negative

• None.

SHANGHAI, Dec. 5, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that after three years of preparation, the Company's MDMOOC platform has established a "Surgical-Interventional-Drug" ("SID") platform for liver cancer comprehensive-disciplinary physician education ("SID Platform"), providing physicians with knowledge and techniques in comprehensive-disciplinary comprehensive management of patients with liver cancer.

According to The Global Cancer Observatory, there were around 400,000 new liver cancer cases in 2020 in China. In the context of the increasing number of liver cancer patients in China, the National Health Commission of the People's Republic of China has promulgated authoritative liver cancer diagnosis and treatment guiding documents, such as the "Standardization of Diagnosis and Treatment for Hepatocellular Carcinoma," "Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma" and "Expert Guidance on the Comprehensive Management of Liver Cancer Patients during the Covid-19 Pandemic" to guide the clinical treatment of liver cancer. In recent years, significant progress has been made in the surgical, interventional, pharmacological and radiological treatment of liver cancer in China.

The SID Platform created by Zhongchao targets physicians from different levels and covers comprehensive disciplines of liver cancer treatment: hepatobiliary surgery, interventional and medical oncology. Led by the Key Opinion Leaders ("KOL") of liver cancer disciplines, the SID Platform designs and provides clinical diagnosis and treatment education courses in liver cancer and provides a technical platform for clinicians to share experiences and discuss clinical challenges. As of today, the courses on the SID Platform were taken approximately 290,000 times by liver cancer physicians. Zhongchao believes that its SID Platform provides a platform for liver cancer physicians, especially for junior and intermediate physicians to present themselves, learn knowledge and techniques, and communicate with peers, which promotes new liver cancer treatment concepts such as conversion therapy, comprehensive patient management and standardized interventional treatments. Zhongchao expects its SID Platform to serve as a new model of promotion and education platform, contribute to the lifelong learning and professional development of liver cancer physicians, and eventually benefit liver cancer patients.

About Zhongchao Inc.

Zhongchao Inc. is an offshore holding company incorporated in the Cayman Islands. It conducts operations in China through the contractual arrangements between its wholly owned subsidiary and PRC operating entities. Zhongchao Inc. is a platform-based internet technology company offering services to patients with oncology and other major diseases. The PRC operating entities provide online healthcare information, professional training and educational services to healthcare professionals under their "MDMOOC" platform (www.mdmooc.org), offer patient management services in the professional field of tumor and rare diseases through Zhongxin, offer internet healthcare services through Zhixun Internet Hospital, and pharmaceutical services through Xinjiang Medical and operate an online information platform, Sunshine Health Forums, to general public. More information about the Company can be found at its investor relations website at http://izcmd.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:  the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the professional training and educational services market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

At the Company: Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 21-3220-5987

Investor Relations: Sherry Zheng  
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com
Phone: +1 718-213-7386

 

View original content:https://www.prnewswire.com/news-releases/zhongchao-inc-established-sid-liver-cancer-comprehensive-disciplinary-physician-education-platform-301691837.html

SOURCE Zhongchao Inc.

FAQ

What is the SID platform launched by Zhongchao Inc. (ZCMD)?

The SID platform is a comprehensive educational platform for liver cancer physicians focusing on surgical, interventional, and drug management.

How many times has the SID platform been accessed by physicians?

The SID platform has been accessed approximately 290,000 times by liver cancer physicians.

Why was the SID platform established by Zhongchao Inc.?

The SID platform was established to enhance physician education in liver cancer management due to the increasing incidence of liver cancer in China.

What are the statistics on liver cancer cases in China?

In 2020, there were around 400,000 new liver cancer cases reported in China.

How does Zhongchao Inc. (ZCMD) support liver cancer treatment guidelines?

Zhongchao's SID platform aligns with the National Health Commission's guidelines for liver cancer diagnosis and treatment.